Characterization of ertapenem-resistant Enterobacterales in Canadian hospitals: 17 years of the CANWARD study (2007–23)
In Canada, ertapenem-resistant Enterobacterales remain uncommon (0.7%). CPE isolates demonstrated higher percent resistant values for multiple antimicrobial classes and harboured more antimicrobial resistance genes than non-CPE isolates. Continued monitoring for ertapenem-resistant Enterobacterales, particularly CPE, is important given their associated multidrug resistance to both established and newer agents.
Authors
- Nicole A. Lerminiaux (ORCID: https://orcid.org/0000-0001-7914-9198)
- Laura F. Mataseje (ORCID: https://orcid.org/0000-0002-8014-1107)
- George R. Golding (ORCID: https://orcid.org/0000-0002-4285-4747)
- Heather J. Adam (ORCID: https://orcid.org/0000-0002-5646-6454)
- Melanie R. Baxter
- Philippe Lagacé‐Wiens (ORCID: https://orcid.org/0000-0002-5826-2869)
- Andrew Walkty (ORCID: https://orcid.org/0000-0003-2880-2104)
- Susan M. Poutanen (ORCID: https://orcid.org/0000-0003-4747-2550)
- Melissa McCracken
- George G. Zhanel (ORCID: https://orcid.org/0000-0002-3238-0082)
- James A. Karlowsky (ORCID: https://orcid.org/0009-0004-3330-0285)
Institutions
- Manitoba Health (CA)
- Public Health Agency of Canada (CA)
- Health Sciences Centre (CA)
- Shared Health (CA)
- Sinai Health System (CA)
- University of Manitoba (CA)
Publication Details
- Journal
- Journal of Antimicrobial Chemotherapy
- Published
- 2025-06-24
- DOI
- https://doi.org/10.1093/jac/dkaf221
- Citations
- 1
- Primary Topic
- Antibiotic Resistance in Bacteria
- Type
- article
- Field-Weighted Citation Impact
- 0.59
Funders
- Pfizer
- University of Manitoba
- Merck Canada
- Sandoz Canada